HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
To evaluate HAIC combined with Sintilimab plus bevacizumab biosimilar for advanced hepatocellular carcinoma.
Trial Details
- NCT ID
- NCT06860490
- Phase
- PHASE2
- Sponsor
- Fudan University
- Status
- RECRUITING
- Cancer Type
- Liver Cancer
- Interventions
- Sintilimab
- Bevacizumab Biosimilar
- HAIC
- Locations (sample)
- Shanghai, Shanghai Municipality, China|31.22222,121.45806
Key Eligibility Criteria
- Written informed consent obtained.
- Age ≥ 18 years at time of study entry.
- Barcelona Clinic Liver Cancer stage C, or stage B not amenable to curative or locoregional therapies.
- HCC confirmed by radiology, histology or cytology.
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Liver Cancer Trials on Trialify →